Toripalimab
- Generic Name
- Toripalimab
- Brand Names
- Loqtorzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1924598-82-2
- Unique Ingredient Identifier
- 8JXN261VVA
- Background
Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).
- Indication
⑴用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤。⑵用于治疗既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌（NPC）。⑶用于治疗既往接受过治疗的局部进展或转移性尿路上皮癌（UC）。⑷用于食管鳞癌一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT
- Conditions
- Interventions
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 198
- Registration Number
- NCT05628922
- Locations
- 🇨🇳
Fudan Universtiy Shanghai Cancer Centre, Shanghai, Shanghai, China
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 139
- Registration Number
- NCT05615974
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
🇨🇳Linyi Cancer Hospital, Linyi, Shandong, China
Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Shouyao Holdings (Beijing) Co. LTD
- Target Recruit Count
- 114
- Registration Number
- NCT05580445
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
- Conditions
- Interventions
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT05539118
- Locations
- 🇨🇳
Air Force Military Medical University/ Fourth Military Medical University, Xi'an, Shaanxi, China
Study of LM-108 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 392
- Registration Number
- NCT05518045
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2022-08-16
- Lead Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT05502393
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhejiang University Medical College, Hangzhou, Zhejiang, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
- Conditions
- Interventions
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2022-08-18
- Target Recruit Count
- 93
- Registration Number
- NCT05493332
To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2022-08-08
- Target Recruit Count
- 20
- Registration Number
- NCT05491694
Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 1
- Registration Number
- NCT05461235
Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 61
- Registration Number
- NCT05420597
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.